Georgetown University, Lombardi Cancer Center Support Grant Competitive Renewal

描述（由申请人提供）：这是乔治敦隆巴迪综合癌症中心（Lombardi） CCSG第20至24年的续期申请。隆巴迪的使命是通过尖端研究、专家和富有同情心的病人护理、未来癌症专家的教育和社区服务来预防、治疗和治愈癌症。伦巴第是美国首都和华盛顿市区唯一一家nci指定的癌症中心。哥伦比亚特区是全国癌症死亡率最高的地区之一。因此，显然需要一个nci指定的综合癌症中心，它可以为癌症护理和预防带来有针对性的、基于证据的战略，以帮助改善社区居民的健康。在目前的申请中，Lombardi包括177名成员（113名正式成员），在12个共享资源的支持下参与了6个研究项目，主要基于两座相邻的建筑。2008年同行评议研究的年度直接资助总额为5300万美元，其中2850万美元来自NCI。这表明与2002年相比，NCI的资金有了显著增加。Lombardi的临床活动是与GU的临床合作伙伴MedStar Health， Inc.共同开展的。2002财年，隆巴迪临床服务中心癌症门诊超过2.2万人次，603名患者参加了隆巴迪临床试验。2008年，癌症门诊就诊人数增加到39000人，其中1169人接受了介入试验。2008年1月，乔治城大学（GU）聘请了一位新主任，医学博士路易斯·韦纳（Louis Weiner），这是对Lombardi成功的坚定不移的高水平承诺的例证。他还担任GU肿瘤科主任，有权招聘教师、控制空间并监督资源分配，以支持隆巴迪的使命。最近几次引人注目的招聘证明了隆巴迪吸引优秀研究人员的能力。隆巴迪大学在基础科学、临床转化研究和人口科学领域的六个研究项目，以及在健康差异和系统医学领域的新的跨领域倡议，证明了隆巴迪大学研究环境的成功。在当前资助期内，Lombardi的研究人员发表了近2000篇同行评议的论文（24%是项目内的，22%是项目间的），对该申请所强调的癌症研究领域（如人类乳头瘤病毒疫苗的开发）产生了持续而强大的影响。在CCSG的持续支持下，Lombardi将继续为癌症研究做出杰出的、高影响力的贡献。

DESCRIPTION (provided by applicant): This is a renewal application for years 20 to 24 of the Georgetown Lombardi Comprehensive Cancer Center (Lombardi) CCSG. Lombardi's mission is to prevent, treat and cure cancers, through cutting-edge research, expert and compassionate patient care, education of future cancer specialists, and service to the community. Lombardi is the only NCI-designated cancer center in the nation's capital and in the Washington metropolitan area. The District of Columbia has among the highest cancer mortality rates in the country. Thus, there is a clear need for an NCI-designated comprehensive cancer center that can bring a targeted, evidence-based strategy to cancer care and prevention to help improve the health of the community's residents. In the present application, Lombardi comprises 177 members (113 full members), participating in six research programs with the support of 12 shared resources, based primarily in two adjacent buildings. Peer-reviewed research annual direct funding for 2008 totaled $53 million, with $28.5 million coming from the NCI. This represents a significant increase in NCI funding compared with 2002. Lombardi clinical activities are carried out in conjunction with GU's clinical partner, MedStar Health, Inc. In FY02, Lombardi clinical services served more than 22,000 outpatient cancer visits, and 603 patients were enrolled on Lombardi clinical trials. Outpatient cancer visits have increased to 39,000 in 2008, with 1,169 people placed on interventional trials. Georgetown University's (GU) unwavering high level of commitment to the success of Lombardi is exemplified by the recruitment of a new Director, Louis Weiner, M.D., in January 2008. He also chairs the GU Department of Oncology, with the authority to recruit faculty, control space, and oversee resource allocation to support Lombardi's mission. Several recent high-profile recruitments attest to Lombardi's ability to attract outstanding researchers. The success of Lombardi's research environment is demonstrated by its six research programs in the areas of basic science, clinical translational research, and population science, coupled with new cross-cutting initiatives in health disparities and systems medicine. Lombardi's researchers published almost 2,000 peer-reviewed manuscripts (24% intraprogrammatic and 22% interprogrammatic) in the current funding period, exerting a sustained and powerful influence on the cancer research fields highlighted in this application, such as the development of human papillomavirus vaccines. With continued CCSG support, Lombardi will continue to make outstanding, high-impact contributions to cancer research. RELEVANCE: This is a renewal application for years 20 to 24 of the Georgetown Lombardi Comprehensive Cancer Center (Lombardi) CCSG, led by Louis Weiner, M.D. Lombardi's mission is to prevent, treat and cure cancers, through cutting-edge research, expert and compassionate patient care, education of future cancer specialists, and service to the community. The success of Lombardi's research environment is demonstrated by its six research programs in the areas of basic science, clinical translational research, and population science. Each program brings together cancer researchers who focus on distinct areas, coupled with new cross-cutting initiatives in health disparities and systems medicine. With continued CCSG support, Lombardi will continue to make outstanding, high impact contributions to cancer research.